Press Release: Novartis Phase III Beovu(R) data -2-

events or otherwise.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives.

As a leading global medicines company, we use innovative science and

digital technologies to create transformative treatments in areas of

great medical need. In our quest to find new medicines, we consistently

rank among the world's top companies investing in research and

development. Novartis products reach nearly 800 million people globally

and we are finding innovative ways to expand access to our latest

treatments. About 110,000 people of more than 140 nationalities work at

Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at

https://twitter.com/novartisnews https://twitter.com/novartisnews

For Novartis multimedia content, please visit

https://www.novartis.com/news/media-library

For questions about the site or required registration, please contact

media.relations@novartis.com

References

1. Brown D, Wolf S, Garweg JG, et al. Brolucizumab for the treatment of

visual impairment due to diabetic macular edema: 52-week results from the

KESTREL & KITE studies. Presented at: The Association for Research in

Vision and Ophthalmology (ARVO) 2021 Annual Meeting. May 2021.

2. Eylea [prescribing information] Tarrytown, NY: Regeneron Pharmaceuticals,

Inc; 2018.

3. Beovu [US prescribing information] East Hanover, NJ. Novartis: 2020.

4. Data on file. KESTREL and KITE Clinical Study Report. Novartis, 2021.

5. Romero-Aroca P. Managing diabetic macular edema: The leading cause of

diabetes blindness. World J Diabetes. 2011;2(6):98-104.

6. National Eye Institute. Macular Edema. Available at:

https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema.

Accessed April 2021.

7. National Eye Institute. Diabetic Retinopathy. Available at:

https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/diabetic-retinopathy.

Accessed April 2021.

8. Beovu [summary of product characteristics] Basel, Switzerland. Novartis:

2020.

9. Pharma Japan. National Health Insurance Pricing. Available at:

https://pj.jiho.jp/sites/default/files/pj/document/2020/05/New%20Drugs%20to%20Be%20Added%20to%20NHI%20Price%20List%20on%20May%2020_1.pdf.

Accessed April 2021.

10. Canadian Agency for Drugs and Technologies in Health. CADTH Canadian Drug

Expert Committee Recommendation. Available at:

https://cadth.ca/sites/default/files/cdr/complete/SR0632%20Beovu%20-%20CDEC%20Final%20Recommendation%20%E2%80%93%20May%2025%2C%202020_for%20posting.pdf.

Accessed April 2021.

11. Beovu [prescription medicine decision summary] Australia. Novartis: 2020.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Peter Zuest Amy Wolf

Novartis External Communications Novartis Division Communications

+ 41 79 899 9812 (mobile) + 41 79 576 07 23 (mobile)

peter.zuest@novartis.com amy.wolf@novartis.com

Julie Masow

Novartis Head US External Engagement

+1 862 579 8456

julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188

(END) Dow Jones Newswires

May 01, 2021 07:05 ET (11:05 GMT)